Triple Negative Breast Cancer Clinical Trials

A listing of 71 Triple Negative Breast Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Triple Negative Breast Cancer

1 - 12 of 71

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 71 active clinical trials seeking participants for Triple Negative Breast Cancer research studies. The states with the highest number of trials for Triple Negative Breast Cancer participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

NCT06449222

Recruiting

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/02/2025

Locations: Arizona Oncology Associates, PC, Tucson, Arizona +61 locations

Arizona Oncology Associates, PC, Tucson, Arizona

Beverly Hills Cancer Center, Beverly Hills, California

Valkyrie Clinical Trials, Los Angeles, California

Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto, California

Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California

Rocky Mountain Cancer Centers (RMCC), Denver, Colorado

Yale University - Yale Cancer Center, New Haven, Connecticut

Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida

Kaiser Permanente - Moanalua Medical Center And Clinic, Honolulu, Hawaii

Orchard Healthcare Research Inc., Skokie, Illinois

Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois

Northwest Cancer Centers, P.C., Dyer, Indiana

Community Health Network, Indianapolis, Indiana

Helen G. Nassif Community Cancer Center, Cedar Rapids, Iowa

Henry Ford Hospital, Detroit, Michigan

HealthPartners Regions Specialty Clinics, Saint Louis Park, Minnesota

Minnesota Oncology - Woodbury Clinic, Woodbury, Minnesota

Bozeman Health Deaconess Hospital Cancer Center, Bozeman, Montana

Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey), New Brunswick, New Jersey

Stony Brook University Hospital, Stony Brook, New York

Clinical Research Alliance Inc., Westbury, New York

FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina

The West Clinic, P.C. d/b/a West Cancer Center, Germantown, Tennessee

University of Tennessee Medical Center, Knoxville, Tennessee

SCRI Oncology Partners, Nashville, Tennessee

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

Ut Health Science Center - San Antonio (UTHSCSA), Cancer Therapy & Research Center, San Antonio, Texas

Bon Secours St. Francis Medical Center, Midlothian, Virginia

Virginia Oncology Associates, Norfolk, Virginia

Northwest Cancer Specialists, Vancouver, Washington

Icon Cancer Care, Wesley Clinic, Auchenflower, Not set

Peninsula Oncology Centre, Frankston, Not set

Peter MacCallum Cancer Centre, Melbourne, Not set

Mater Hospital Sydney, Sydney, Not set

Westmead Hospital, Westmead, Not set

Baskent Universitesi Tip Fakultesi Adana Hastanesi, Adana, Not set

Medical Park Seyhan Hospital, Adana, Not set

Adana City Training and Research Hospital, Adana, Not set

Sakarya University - Faculty of Medicine, Adapazarı, Not set

Gulhane Egitim ve Arastirma Hastanesi, Ankara, Not set

Hacettepe Universitesi Kanser Enstitusu, Ankara, Not set

Sbu Dr.A.Y. Ankara Onkoloji SUAM, Ankara, Not set

Memorial Ankara Hospital, Ankara, Not set

Ankara City Hospital, Ankara, Not set

Gaziantep Sanko University Medical Faculty, Gaziantep, Not set

Koc Universitesi Hastanesi (Koc University Hospital), Istanbul, Not set

Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Not set

Istinye Universitesi Bahcesehir Liv Hospital, Istanbul, Not set

Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Not set

Yeditepe University Hospital, Istanbul, Not set

Medical Point Izmir Hospital, İzmir, Not set

Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Not set

Acibadem Adana Hospital, Seyhan, Not set

Gazi University Medical Faculty, Yenimahalle, Not set

Stoke Mandeville Hospital - Buckinghamshire Healthcare NHS Trust, Aylesbury, Not set

Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital, Cottingham, Not set

Edinburgh Cancer Centre-Western General Hospital, Edinburgh, Not set

St James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, Not set

St Bartholomew's Hospital - Barts Health NHS Trust, London, Not set

University College London Hospitals NHS Foundation Trust, London, Not set

Sarah Cannon Research Institute, London, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Conditions: Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers

Learn More ›

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

NCT05989828

Recruiting

This phase Ib trial tests the safety, side effects and best dose of anti-HLA-A2/NY-ESO-1 T-cell receptor (TCR)-transduced autologous T lymphocytes (A2-ESO-1 TCR-T cells) in treating patients with NY-ESO-1 overexpression positive triple negative breast cancer (TNBC) that has come back after a period of improvement (relapsed/recurrent) or that does not respond to treatment (refractory), and that may have spread from where it first started (primary site) to nearby tissue, lymph nodes (advanced) or to other places in the body (metastatic). NY-ESO-1 is an antigen found on the surface of many different types of tumor cells including TNBC. Antigens make it possible for immune cells to recognize and kill germ cells that invade the body, however, it is more difficult for immune cells to recognize antigens on tumor cells. T cells are a special type of immune cell in the blood. These T cells may be trained to recognize the NY-ESO-1 antigen on tumor cells, allowing the T cells to attack and kill those tumor cells. The A2-ESO-1 TCR-T cells are T cells that have been removed from the patient's blood through a process called leukapheresis and then changed in the laboratory to recognize NY-ESO-1 on tumor cells. When given back to the patient, these A2-ESO-1 TCR-T cells find and attack tumor cells that express NY-ESO-1. Chemotherapy drugs, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. They are given before the T cells to support optimum activity of the A2-ESO-1 TCR-T cells. IL-2 (aldesleukin) is in a class of drugs known as cytokines. It is a man-made version of a naturally occurring protein that stimulates the body to produce other chemicals which increase the body's ability to fight cancer. A2-ESO-1 TCR-T cells may kill more tumor cells in patients with recurrent or refractory advanced or metastatic TNBC that overexpresses NY-ESO-1. Read Less

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

07/01/2025

Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California

Conditions: Triple Negative Breast Cancer

Learn More ›

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192

Recruiting

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

06/27/2025

Locations: Stanford University Medical Center, Stanford, California +8 locations

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer

Learn More ›

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

NCT04677816

Recruiting

A two arm pilot study investigating the rate of pathologic complete response in patients with vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant chemotherapy + vitamin D supplementation, including an observational arm to describe response in patients who are not deficient. Investigators hypothesize that vitamin D supplementation during neoadjuvant chemotherapy in operable triple negative breast cancer patients with vitamin D deficiency, will increase the rate... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/26/2025

Locations: Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina

Conditions: Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer

Learn More ›

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654

Recruiting

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: Alabama Oncology, Birmingham, Alabama +223 locations

Alabama Oncology, Birmingham, Alabama

Clearview Cancer Institute, Huntsville, Alabama

Palo Verde Hematology Oncology, Glendale, Arizona

Mayo Clinic Hospital, Phoenix, Arizona

Arizona Oncology Associates, Prescott Valley, Arizona

Alta Bates Summit Medical Center, Berkeley, California

Community Cancer Institute, Clovis, California

PIH Health Whittier Hospital, Downey, California

Compassionate Cancer Care Medical Group - Inc, Fountain Valley, California

Los Angeles Cancer Network, Los Angeles, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

Cedars-Sinai Cancer at Beverly Hills, Los Angeles, California

Hoag Memorial Hospital Presbyterian, Newport Beach, California

Emad Ibrahim, MD, INC, Redlands, California

Sutter Institute for Medical Research, Sacramento, California

UCSF Medical Center, San Francisco, California

Sansum Clinic, Santa Barbara, California

Stockton Hematology Oncology Medical Group, Stockton, California

University of Colorado Cancer Center, Aurora, Colorado

Norwalk Hospital, Danbury, Connecticut

Stamford Hospital, Stamford, Connecticut

Morton Plant Hospital - Bay Care, Clearwater, Florida

University of Florida, Gainesville, Florida

Mayo Clinic Florida, Jacksonville, Florida

Cancer Specialists of North Florida, Jacksonville, Florida

Jupiter Medical Center, Jupiter, Florida

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida

Midland Florida Clinical Research Center, L, Orange City, Florida

Orlando Health, Orlando, Florida

Cancer Care Centers of Brevard, Inc, Palm Bay, Florida

Memorial Healthcare System, Pembroke Pines, Florida

Sacred Heart Medical Oncology Group, Pensacola, Florida

Sylvester Comprehensive Cancer Center, Plantation, Florida

Cleveland Clinic Florida, Martin North Hospital, Stuart, Florida

St. Joseph's Hospital, Tampa, Florida

Weston Hospital, Weston, Florida

University Cancer & Blood Center, LLC., Athens, Georgia

Piedmont Cancer Institute, Atlanta, Georgia

Northside Hospital, Atlanta, Georgia

Northwest Georgia Oncology Centers, PC, Marietta, Georgia

Pearlman Cancer Center, Valdosta, Georgia

St Lukes Mountain States Tumor Institute, Boise, Idaho

Kootenai Health, Coeur d'Alene, Idaho

Northwestern Medicine, Chicago, Illinois

Rush University Medical Center, Chicago, Illinois

University of Illinois, Chicago, Illinois

University of Chicago Medical Center, Chicago, Illinois

NorthShore University Healthsystem, Evanston, Illinois

Edward Hospital, Naperville, Illinois

West Suburban Medical Center- River Forest, River Forest, Illinois

Edward H. Kaplan MD & Associates - Hematology/Oncology of the North Shore, Skokie, Illinois

Springfield Clinic LLP, Springfield, Illinois

Carle Cancer Center, Urbana, Illinois

Franciscan Health Indianapolis, Indianapolis, Indiana

Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana

IU Health Arnett Hospital, Lafayette, Indiana

Franciscan Health Munster, Munster, Indiana

Mercy Medical Center, Cedar Rapids, Iowa

Mission Cancer & Blood - John Stoddard Cancer Center, Des Moines, Iowa

University of Iowa Hospitals and Clinics, Fairfield, Iowa

University of Kentucky, Lexington, Kentucky

Norton Healthcare, Inc., Louisville, Kentucky

Mercy Health, Paducah, Kentucky

Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana

University Medical Center New Orleans, New Orleans, Louisiana

New England Cancer Specialists, Scarborough, Maine

Sinai Hospital of Baltimore, Inc., Baltimore, Maryland

St. Agnes Hospital, Baltimore, Maryland

Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Medstar Franklin Square Medical Center, Baltimore, Maryland

American Oncology Partners of Maryland, PA, Bethesda, Maryland

James M Stockman Cancer Institute, Frederick, Maryland

Greater Baltimore Medical Center, Towson, Maryland

Tufts Medical Center, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Baystate Medical Center Inc., Springfield, Massachusetts

University of Massachusetts Worcester, Worcester, Massachusetts

Henry Ford Health System, Detroit, Michigan

Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan

Ascension, Grosse Pointe Woods, Michigan

William Beaumont Hospital, Royal Oak, Michigan

Ascension Providence Hospital Southfield Cancer Center, Southfield, Michigan

Trinity Health St. Joseph Mercy Ann Arbor, Ypsilanti, Michigan

Minnesota Oncology Hematology, PA, Maplewood, Minnesota

Virginia Piper Cancer Center (Allina Health), Minneapolis, Minnesota

University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota

Mayo Clinic Rochester, Rochester, Minnesota

Metro Minnesota Community Oncology, Saint Louis Park, Minnesota

Baptist Clinical Research Institute, Saint Louis, Missouri

Mercy Hospital, Saint Louis, Missouri

Mary Lanning Healthcare - Morrison Cancer Center, Hastings, Nebraska

Oncology Hematology West - Methodist, Omaha, Nebraska

Nebraska Methodist Hospital (change from Chi Health Bergan Mercy), Omaha, Nebraska

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Cancer Care & Hematology Specialists, Reno, Nevada

Regional Cancer Care Associates LLC, East Brunswick, New Jersey

Hunterdon Medical Center, Flemington, New Jersey

Summit Medical Group, P.A., Florham Park, New Jersey

Rutgers Health, New Brunswick, New Jersey

Overlook Medical Center, Summit, New Jersey

University of New Mexico, Albuquerque, New Mexico

San Juan Oncology Associates, Farmington, New Mexico

New York Oncology Hematology (NYOH), Amsterdam, New York

Montefiore Medical Center, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

Hematology Oncology Associates of Central New York, PC, East Syracuse, New York

Northwell Health, Lake Success, New York

Laura and Isaac Perlmutter Cancer Canter, New York, New York

Lipson Cancer Institute - Linden Oaks, Rochester, New York

New York Cancer and Blood Specialists, Shirley, New York

Stony Brook Medicine, Stony Brook, New York

SUNY Upstate Medical University, Syracuse, New York

Clinical Research Alliance, Westbury, New York

White Plains Hospital Physician Associates, White Plains, New York

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Duke Cancer Institute, Durham, North Carolina

Cone Health Medical Group (Moses Cone Health System), Greensboro, North Carolina

East Carolina University Health Medical Center, Greenville, North Carolina

FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina

UNC Rex Cancer Center, Raleigh, North Carolina

UNC Nash Cancer Center, Rocky Mount, North Carolina

Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina

Good Samaritan Hospital, Cincinnati, Ohio

Oncology Hematology Care, Inc., Cincinnati, Ohio

Ohio State University CRS, Columbus, Ohio

Ohio Health Research Institute, Columbus, Ohio

Anita Stewart Oncology Center, Columbus, Ohio

Toledo Clinic Cancer Center, Toledo, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

St. Charles Health System, Inc. DBA St. Charles Medical Center, Bend, Oregon

Samaritan Hospital, Corvallis, Oregon

Willamette Valley Cancer Institute and Research Center, Eugene, Oregon

Asante Rogue Regional Medical Center, Medford, Oregon

Providence Cancer Institute - Oncology Clinical Trials, Portland, Oregon

Oregon Health & Science University, Portland, Oregon

Saint Luke's University Hospital, Bethlehem, Pennsylvania

Lancaster General Health, Lancaster, Pennsylvania

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania

Guthrie Clinical Research, Sayre, Pennsylvania

Reading Hospital and Medical Center, West Reading, Pennsylvania

Lankenau Medical Center, Wynnewood, Pennsylvania

Cancer Care Associates of York, York, Pennsylvania

Providence Health, Providence, Rhode Island

Medical University of South Carolina, Charleston, South Carolina

Spartanburg Medical Center, Spartanburg, South Carolina

Monument Health Cancer Care Institute, Rapid City, South Dakota

Avera Cancer Institute, Sioux Falls, South Dakota

Ballad Health Cancer Care - Kingsport, Kingsport, Tennessee

Center for Biomedical Research, LLC, Knoxville, Tennessee

University of Tennessee, Knoxville, Tennessee

Hendrick Health System, Abilene, Texas

Texas Oncology, Austin, Texas

Texas Oncology, El Paso, Texas

MD Anderson Cancer Center, Houston, Texas

Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas

Texas Oncology, San Antonio, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Virginia Commonwealth University Medical Center, Richmond, Virginia

Oncology and Hematology Associates of Southwest Virginia, Inc, Wytheville, Virginia

Providence Regional Cancer System, Lacey, Washington

MultiCare Regional Cancer Center - Tacoma, Puyallup, Washington

Northwest Medical Specialties, PLLC, Puyallup, Washington

University of Washington, Renton, Washington

Medical Oncology Associates, Spokane, Washington

West Virginia University Hospital, Morgantown, West Virginia

ThedaCare Regional Cancer Center, Appleton, Wisconsin

Ascension St. Francis Reiman Cancer Center, Franklin, Wisconsin

HSHS Saint Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin

University of Wisconsin, Madison, Wisconsin

Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, New South Wales

Lake Macquarie Private Hospital, Gateshead, New South Wales

Monash Medical Centre, Clayton, Victoria

Pôle Santé Léonard De Vinci - ROC37, Chambray les Tours, Not set

Clinique Victor Hugo, Le Mans, Not set

Hôpital Privé Jean Mermoz, Lyon, Not set

Hopital Privé des Côtes d'Armor - Centre CARIO-HPCA, Plerin, Not set

Centre Eugène Marquis, Rennes cedex, Not set

Oncopole Claudius Regaud - IUCT-O, Toulouse, Not set

Hämatologie-Onkologie im Zentrum MVZ GmbH, Augsburg, Not set

Schwanebecker Chaussee 50, Berlin, Not set

Teutoburger Str. 60, Bielefeld, Not set

Josef-Albers-Str.70, Bottrop, Not set

Studien GbR Braunschweig, Braunschweig, Not set

Hämato-Onkologische Praxis im Medicum, Bremen, Not set

St. Johannes Hospital, Dortmund, Not set

Klinikum Esslingen, Esslingen, Not set

MVZ II der Niels Stensen Kliniken, Georgsmarienhütte, Not set

Moorkamp 2-6, Hamburg, Not set

Edgar-von-Gierke-Straße 2, Karlsruhe, Not set

Elisabeth Krankenhaus Brustzentrum, Kassel, Not set

InVO - Institut für Versorgungsforschung in der Onkologie GbR / Praxis für Hämatologie und Onkologie, Koblenz, Not set

St. Elisabeth Krankenhaus GmbH, Köln, Not set

Universitätsklinikum Mannheim, Mannheim, Not set

Elisabethenstr. 19, 88212 Ravensburg, Ravensburg, Not set

Harsefelderstraße 8, Stade, Not set

Böheimstr. 37, Stuttgart, Not set

Calwerstrasse 7, Tuebingen, Not set

Klinikum Worms Frauenklinik, Worms, Not set

Helios University Hospital University Witten/Herdecke, Wuppertal, Not set

St James's Hospital, Dublin, Not set

Medical Oncology Unit. A Coruña University Hospital, A Coruña, Not set

ICO Badalona - Hospital Germans Trias I Pujol, Badalona, Not set

Hospital Universitary of Cruces, Barakaldo, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital Universitario San Pedro de Alcántara, Caceres, Not set

Consorcio Hospitalario Provincial de Castellón, Castellón, Not set

Hospital General Universitario De Elche, Elche, Not set

Hospital Galdakao, Galdakao, Not set

Hospital Universitario Virgen de las Nieves, Granada, Not set

Hospital Universitario Clínico San Cecilio, Granada, Not set

Hospital Universitario de Jaen, Jaen, Not set

Hospital Universitario Virgen de la Victoria, Malaga, Not set

Althaia Xarxa Assistencial de Manresa, Manresa, Not set

Hospital Universitario Morales Meseguer, Murcia, Not set

Clínica Universidad de Navarra - Madrid, Pamplona, Not set

HU Marqués de Valdecilla, Santander, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

Hospital Quironsalud Sagrado Corazón, Seville, Not set

Hospital Clínico Universitario de Valencia, Valencia, Not set

Hospital Clinico Universitario de Valladolid, Valladolid, Not set

Isabel la Catolica nº 1-3, Zaragoza, Not set

Conditions: Triple Negative Breast Cancer

Learn More ›

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

NCT06238479

Recruiting

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/18/2025

Locations: AdventHealth Orlando, Orlando, Florida +24 locations

AdventHealth Orlando, Orlando, Florida

Emory University, Atlanta, Georgia

Massachusetts General Hospital, Boston, Massachusetts

Washington University School of Medicine, Saint Louis, Missouri

Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

UT Southwestern Medical Center, Dallas, Texas

South Texas Accelerated Research Therapeutics (START), San Antonio, Texas

Icon Cancer Centre Kurralta Park, Kurralta Park, South Australia

Austin Health, Heidelberg, Victoria

Institut Jules Bordet, Anderlecht, Bruxelles-Capitale, Région De

Centre Oscar Lambret, Lille, Nord-Pas-de-Calais

Institut de cancérologie Strasbourg Europe, Strasbourg, Strasbourg, Alsace

Centre Leon Berard, Lyon Cedex 08, Not set

Institut Paoli-Calmettes, Marseille, Not set

Gustave Roussy, Villejuif Cedex, Not set

National Cancer Center Hospital East, Kashiwa, Chiba

The Cancer Institute Hospital of JFCR, Koto City, Tokyo

National Cancer Center Hospital, Chuo-Ku, Not set

Kyoto University Hospital, Kyoto, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

MD Anderson Cancer Center, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Virgen Del Rocio, Sevilla, Not set

Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer

Learn More ›

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

NCT06435351

Recruiting

This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/17/2025

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: Breast Cancer, Triple Negative Breast Cancer

Learn More ›

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

NCT06999187

Recruiting

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/17/2025

Locations: Dren Investigational Site, Denver, Colorado +9 locations

Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma

Learn More ›

A Study of XMT-1660 in Participants With Solid Tumors

NCT05377996

Recruiting

A Study of XMT-1660 in Solid Tumors

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/13/2025

Locations: UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California +21 locations

Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma

Learn More ›

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

NCT06799065

Recruiting

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/12/2025

Locations: Florida Cancer Specialists, Sarasota, Florida +3 locations

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer

Learn More ›

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

NCT05809752

Recruiting

The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/11/2025

Locations: Moffitt Cancer Center, Tampa, Florida +2 locations

Conditions: Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer

Learn More ›

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

NCT04468061

Recruiting

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * Sacituzumab govitecan (Trodelvy™;IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/04/2025

Locations: Stamford Hospital, Stamford, Connecticut +10 locations

Conditions: Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative

Learn More ›

1 - 12 of 71